Astron Multigrain Ltd. IPO

Pursuant to Regulation 30 and Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Astron Multigrain has informed that it enclosed the 8th Annual Report of the Company for the financial year 2025-26 together with the Notice of the 8th Annual General Meeting (‘aAGM’) to be held on Friday, September 25, 2026 at 11:30 AM IST through Video Conferencing / Other Audio Visual Means (‘VC/OAVM’) in accordance with the relevant circulars issued by the Ministry of Corporate Affairs (‘MCA Circulars’) and the Securities and Exchange Board of India, which have permitted the conduct of Annual General Meetings by companies through VC/OAVM. Pursuant to the relevant circulars issued by the Ministry of Corporate Affairs, the Notice convening the AGM and the Annual Report 2025-26 are being sent by e-mail to those Members who have registered their e-mail address with the Company / its Registrar and Share Transfer Agent / Depository Participants (in the case of demat holdings). A letter containing the web-link giving the exact path where the complete details of the Notice of AGM and the Annual Report 2025-26 are available is being sent to those Members who have not registered their e-mail address. The 8th Annual Report and the Notice of the 8th AGM are also being made available on the website of the Company at www.astronmultigrain.co.in and on the website of BSE at www.bseindia.com. 

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Rubicon Research has informed that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection (triggered by a product filing) of the company’s manufacturing facility located at Plot No. K30/4 & 30/5, Additional M.I.D.C., Anand Nagar, Ambernath, Maharashtra, India from Wednesday, 21 October 2026 to Thursday, 29 October 2026. This was a comprehensive GMP inspection in addition to the product application under review. Upon conclusion, a Form 483 containing 3 observations with respect to system improvement and 2 observations with respect to product application under review were issued, all 5 of which are procedural in nature and do not relate to data integrity. The company is confident of working closely with the regulator to successfully conclude the evaluation in a timely manner. All its manufacturing as well as R&D facilities have now been inspected by the US FDA in the recent past and it has enclosed the status of all its operational facilities.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Fabtech Technologies has informed that it enclosed the Investor Presentation in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026.

The above information is a part of company’s filings submitted to BSE.

With reference to the clarification dated October 27, 2026, regarding the significant movement in the price of the securities of the Company, NMS Global has submitted: The Company is not aware of any undisclosed material event, information, or development that would require disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which could have a bearing on the movement in the price of its securities. The Company has been making disclosures to the Stock Exchanges from time to time in accordance with the applicable provisions of the SEBI (LODR) Regulations, 2015. The Company remains committed to ensuring timely disclosure of all material information and maintaining transparency with its shareholders and the investing public. The movement in the price of the Company's securities appears to be market-driven, and the Company is not in a position to comment on the specific reasons for such movement. The company has confirmed that, should any material event or information requiring disclosure arise, the Company shall make the requisite disclosure to the Stock Exchanges in accordance with applicable regulatory requirements.

The above information is a part of company’s filings submitted to BSE.